| Segment Information |
10. SEGMENT INFORMATION
We follow the accounting
guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based
on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker
organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations
are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in five reportable segments,
each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii)
Anti-Viral Therapeutics, (iv) Cancer Diagnostics and (v) our legacy Patent Licensing activities. The following represents selected
financial information for our segments for the three and nine months ended July 31, 2020 and 2019 and as of July 31, 2020 and October
31, 2019:
| |
|
For the Three Months Ended
July 31, |
|
|
For the Nine Months Ended
July 31, |
|
| |
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
| Net Loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
(402,223 |
) |
|
$ |
(723,128 |
) |
|
$ |
(1,527,586 |
) |
|
$ |
(4,240,347 |
) |
| Cancer Vaccines |
|
|
(172,881 |
) |
|
|
(573,005 |
) |
|
|
(538,748 |
) |
|
|
(573,005 |
) |
| Anti-Viral Therapeutics |
|
|
(268,704 |
) |
|
|
- |
|
|
|
(578,208 |
) |
|
|
- |
|
| Cancer Diagnostics |
|
|
(1,727,256 |
) |
|
|
(876,667 |
) |
|
|
(5,196,929 |
) |
|
|
(3,929,021 |
) |
| Patent Licensing |
|
|
(5,723 |
) |
|
|
6,752 |
|
|
|
(9,881 |
) |
|
|
(965,218 |
) |
| Total |
|
$ |
(2,576,787 |
) |
|
$ |
(2,166,048 |
) |
|
$ |
(7,851,352 |
) |
|
$ |
(9,707,591 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total operating costs and expenses |
|
$ |
2,584,053 |
|
|
$ |
2,184,412 |
|
|
$ |
7,884,059 |
|
|
$ |
10,011,374 |
|
| Less non-cash share-based compensation |
|
|
(1,041,799 |
) |
|
|
(830,898 |
) |
|
|
(3,173,219 |
) |
|
|
(4,902,512 |
) |
| Operating costs and expenses excluding non-cash share-based compensation |
|
$ |
1,542,254 |
|
|
$ |
1,353,514 |
|
|
$ |
4,710,840 |
|
|
$ |
5,108,862 |
|
| Operating costs and expenses excluding non-cash share based compensation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
182,007 |
|
|
$ |
442,621 |
|
|
$ |
752,170 |
|
|
$ |
1,688,301 |
|
| Cancer Vaccines |
|
|
70,061 |
|
|
|
407,010 |
|
|
|
235,391 |
|
|
|
407,010 |
|
| Anti-Viral Therapeutics |
|
|
149,075 |
|
|
|
- |
|
|
|
370,093 |
|
|
|
- |
|
| Cancer Diagnostics |
|
|
1,136,629 |
|
|
|
487,169 |
|
|
|
3,345,441 |
|
|
|
1,905,137 |
|
| Patent Licensing |
|
|
4,482 |
|
|
|
16,714 |
|
|
|
7,745 |
|
|
|
1,108,414 |
|
| Total |
|
$ |
1,542,254 |
|
|
$ |
1,353,514 |
|
|
|
4,710,840 |
|
|
$ |
5,108,862 |
|
| |
|
July 31,
2020 |
|
|
October 31,
2019 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
4,110,341 |
|
|
$ |
2,382,460 |
|
| Cancer Vaccines |
|
|
1,575,525 |
|
|
|
489,881 |
|
| Anti-Viral Therapeutics |
|
|
3,349,814 |
|
|
|
- |
|
| Cancer Diagnostics |
|
|
78,723 |
|
|
|
3,119,246 |
|
| Patent Licensing |
|
|
247,378 |
|
|
|
302,106 |
|
| Total |
|
$ |
9,361,781 |
|
|
$ |
6,293,693 |
|
Operating costs and expenses
excluding non-cash share-based compensation expense is the measurement the chief operating decision-maker uses in managing the
enterprise.
|